ArticleAdvances in therapy2023
Projecting the Epidemiological and Economic Impact of Chronic Kidney Disease Using Patient-Level Microsimulation Modelling: Rationale and Methods of Inside CKD.
Article in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- A Systematic Literature Review on the Use of Dried Biofluid Microsampling in Patients With Kidney Disease.Journal of clinical laboratory analysis · 2024Pooled it
- Cost-Utility Analysis of Accelerated and Standard Strategies for Renal Replacement Therapy Initiation.JAMA network open · 2025Trial
- Effect of exercise-based rehabilitation on functional capacity and renal function in type 2 diabetes mellitus with nephropathy: a randomized controlled trial.International urology and nephrology · 2024Trial
- Building healthier communities: effectiveness and cost-sustainability of the ASL3 GENESIS program for chronic diseases prevention.Aging clinical and experimental research · 2026Article
- Technological Innovations and the Translational Path of Kidney Organoids.Biomedicines · 2026Review
- Article
- Screen, Stratify, and Treat: Data to Drive Worldwide CKD Health Policy.Kidney international reports · 2025Article
- "Kidney international reports · 2025Article
- Impact of Improved Diagnosis and Treatment on Holistic CKD Burden.Kidney international reports · 2025Article
- Aptamer-targeted anti-miR RNA construct based on 3WJ as a new approach for the treatment of chronic kidney disease in an experimental model.Gene therapy · 2025Article
- Holistic Impact of CKD: A Clinical, Economic, and Environmental Analysis by IMPACT CKD.Kidney international reports · 2025Article
- Identification and validation of an explainable early-stage chronic kidney disease prediction model: a multicenter retrospective study.EClinicalMedicine · 2025Article
- Epidemiology and hospitalization costs of chronic kidney disease in Romania.Health economics review · 2025Article
- Inside CKD: Cost-Effectiveness of Multinational Screening for CKD.Kidney international reports · 2025Article
- Long-term health consequences and costs of changes in alcohol consumption in England during the COVID-19 pandemic.PloS one · 2025Article
- The Clinical and Economic Burden of Chronic Kidney Disease in Poland: Inside Patient-Level Microsimulation Modelling of CKD.Journal of clinical medicine · 2024Article
- Development and validation of a chronic kidney disease progression model using patient-level simulations.Renal failure · 2024Article
- Projecting the Population Level Burden of CKD Progression According to Urine Albumin-to-Creatinine Ratio Categories.Kidney international reports · 2024Article
- IMPACT CKD: Holistic Disease Model Projecting 10-Year Population Burdens.Kidney international reports · 2024Article
- Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population.Advances in therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney disease (CKD) is a serious condition associated with significant morbidity and healthcare costs. Despite this, early-stage CKD is often undiagnosed, and globally there is substantial variation in the effectiveness of screening and subsequent management. Microsimulations can estimate future epidemiological costs, providing useful insights for clinicians, policymakers and researchers. Inside CKD is a programme designed to analyse the projected prevalence and burden of CKD for countries across the world, and to simulate hypothetical intervention strategies that can then be assessed for potential impact on health and economic outcomes at a national and a global level.
methodsInside CKD uses a population-based approach that creates virtual individuals for a given country, with this simulated population progressing through a microsimulation in 1-year increments. A series of data inputs derived from national statistics and key literature defined the likelihood of a change in health state for each individual. Input modules allow for the input of nationally specific demographic and CKD status (including prevalence, diagnosis rates, disease stage and likelihood of renal replacement therapy), disease progression, critical comorbidities, and mortality. Health economics are reflected in cost data and a flexible intervention module allows for the testing of hypothetical policies-such as screening strategies-that may alter disease progression and outcomes.
resultsUsing input data from the UK as a case study and a 6-year simulation period, Inside CKD estimated a prevalence of 9.2 million individuals (both diagnosed and estimated undiagnosed) with CKD by 2027 and a 5.0% increase in costs for diagnosed CKD and renal replacement therapy. External validation and sensitivity analyses confirmed the observed trends, substantiating the robustness of the microsimulation.
conclusionsUsing a microsimulation approach, Inside CKD extends the reach of current CKD policy analyses by factoring in multiple inputs that reflect national healthcare systems and enable analysis of the effect of multiple hypothetical screening scenarios on disease progression and costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.